Bulletin
Investor Alert

Cyclerion Therapeutics Inc.

NAS: CYCN

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Cyclerion Therapeutics Inc.

After Hours

 --Quotes are delayed by 20 min

Feb 1, 2023, 5:14 p.m.

CYCN
/zigman2/quotes/207301221/composite

$

0.64

Change

-0.0012 -0.19%

Volume

Volume 8

Quotes are delayed by 20 min

/zigman2/quotes/207301221/composite

Today's close

$ 0.67

$ 0.64

Change

-0.03 -4.07%

Day low

Day high

$0.64

$0.72

Open

52 week low

52 week high

$0.35

$1.49

Open
Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Cyclerion Therapeutics Inc.

View Ratios
Fiscal year is January-December. All values USD millions. 20172018201920202021 5-year trend
Sales/Revenue --4.51M2.3M3.94M
Cost of Goods Sold (COGS) incl. D&A 1.75M1.53M--472,000
COGS excluding D&A -----
Depreciation & Amortization Expense 1.75M1.53M2.7M2.3M472,000
Depreciation 1.75M1.53M2.7M2.3M472,000
Amortization of Intangibles -----
Gross Income (1.75M)(1.53M)--3.47M
20172018201920202021 5-year trend
SG&A Expense 92.18M113.72M121.91M77.03M49.18M
Research & Development 78.8M87.72M95.14M56.41M37.64M
Other SG&A 13.37M26.01M26.77M20.62M-
Other Operating Expense -----
Unusual Expense --4.19M1.2M(405,000)
EBIT after Unusual Expense --(124.29M)(78.23M)(45.31M)
Non Operating Income/Expense --(751,000)429,000(6.34M)
Non-Operating Interest Income --2.03M--
Equity in Affiliates (Pretax) -----
Interest Expense -----
Gross Interest Expense -----
Interest Capitalized -----
Pretax Income (93.92M)(115.25M)(123.01M)(77.8M)(51.65M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (93.92M)(115.25M)(123.01M)(77.8M)(51.65M)
Minority Interest Expense -----
Net Income (93.92M)(115.25M)(123.01M)(77.8M)(51.65M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (93.92M)(115.25M)(123.01M)(77.8M)(51.65M)
Preferred Dividends -----
Net Income Available to Common (93.92M)(115.25M)(123.01M)(77.8M)(51.65M)
EPS (Basic) (3.43)(4.21)(4.49)(2.56)(1.32)
Basic Shares Outstanding 27.4M27.4M27.38M30.4M39.14M
EPS (Diluted) (3.43)(4.21)(4.49)(2.56)(1.32)
Diluted Shares Outstanding 27.4M27.4M27.38M30.4M39.14M
EBITDA (92.18M)(113.72M)(117.4M)(74.74M)(45.24M)
Copyright 2023 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Link to MarketWatch's Slice.